

THE 25 AUTHORISED ATMPs IN THE EU *(latest update March 2023)*

Name	Type	Domain	MA Year	MA Type	Current status
ChondroCelect	TEP	Orthopaedic	2009	Standard	Withdrawn, 29-07-2016
Glybera	GTMP	Gastrology	2012	Exceptional	Withdrawn, 28-10-2017
MACI	Comb. TEP	Orthopaedic	2013	Standard	Withdrawn, 1-7-2018
Provenge	CTMP	Oncology	2013	Standard	Withdrawn, 6-5-2015
Holoclax	TEP	Ophthalmology	2015	Conditional	Positive
Imlygic	GTMP	Oncology	2015	Standard	Positive
Strimvelis	GTMP	Immunology	2016	Standard	Positive
Zalmoxis	CTMP	Graft vs. host	2016	Conditional	Withdrawn, 9-10-2019
Spherox	TEP	Orthopaedic	2017	Standard	Positive
Alofisel	CTMP	Gastrology	2018	Standard	Positive
Yescarta	GTMP	Immunocellular cancer	2018	Standard (PRIME)	Positive
Kymriah	GTMP	Immunocellular cancer	2018	Standard (PRIME)	Positive
Luxturna	GTMP	Ophthalmology	2018	Standard	Positive
Zynteglo	GTMP	Beta-Thalassemia	2019	Conditional/Accelerated (PRIME)	Withdrawn, 24-3-2022
Zolgensma	GTMP	Muscular Atrophy	2020	Conditional/Accelerated (PRIME)	Positive
Libmeldy	GTMP	Leukodystrophy, Metachromatic	2020	Accelerated	Positive
Tecartus	GTMP	Lymphoma, Mantle-Cell	2020	Conditional/Accelerated (PRIME)	Positive
Skysona	GTMP	Cerebral adreno leuko-dystrophy	2021	Accelerated (PRIME) reverted to Standard	Withdrawn, 18-11-2021
Abecma	GTMP	Cancer of plasma cells	2021	Conditional/Accelerated (PRIME)	Positive
Breyanzi	GTMP	Blood cancer	2022	Accelerated (PRIME)	Positive
Upstaza	GTMP	Amino Acid Metabolism, Inborn Errors	2022	Exceptional	Positive
Carvykti	GTMP	Multiple Myeloma cancer of the bone marrow	2022	Conditional (PRIME)	Positive
Roctavian	GTMP	Haemophilia A	2022	Conditional	Positive
Ebvallo	CTMP	Lymphoproliferative Disorders	2022	Exceptional (PRIME)	Positive
Hemgenix	GTMP	Haemophilia B	2023	Conditional (PRIME)	Positive

Latest update – March 2023, TEP: Tissue Engineered Product; GTMP: Gene Therapy Medicinal Product; CTMP: Cell Therapy Medicinal Product; MA: Marketing Authorisation